Gilead Steals The Show At Liver Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
It was all good news for Gilead at the American Association for the Study of Liver Disease meeting in Boston Nov. 10-13, where the company produced evidence it can develop an effective and entirely unpartnered all-oral combination therapy against hepatitis C – but the combination still has to hold up in Phase III trials.